Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-16-533881
Filing Date
2016-04-07
Accepted
2016-04-07 16:28:42
Documents
7
Effectiveness Date
2016-04-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE MERGER PROXY STATEMENT d159357ddefm14a.htm DEFM14A 2612503
2 GRAPHIC g159357g00s29.jpg GRAPHIC 91149
3 GRAPHIC g159357g46m77.jpg GRAPHIC 94519
4 GRAPHIC g159357g68a63.jpg GRAPHIC 24968
5 GRAPHIC g159357g95n07.jpg GRAPHIC 25514
6 GRAPHIC g159357pc1.jpg GRAPHIC 137358
7 GRAPHIC g159357pc2.jpg GRAPHIC 107391
  Complete submission text file 0001193125-16-533881.txt   3276574
Mailing Address 1035 O?BRIEN DRIVE, SUITE A MENLO PARK CA 94025
Business Address 1035 O?BRIEN DRIVE, SUITE A MENLO PARK CA 94025 650-272-6269
Avalanche Biotechnologies, Inc. (Filer) CIK: 0001501756 (see all company filings)

IRS No.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-36579 | Film No.: 161560403
SIC: 2836 Biological Products, (No Diagnostic Substances)